Patents by Inventor Luc J. Farmer

Luc J. Farmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20100173851
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: June 3, 2009
    Publication date: July 8, 2010
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7683033
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: February 4, 2005
    Date of Patent: March 23, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin M. Cottrell, John J. Court, David D. Deininger, Luc J. Farmer, Janos Pitlik, Robert B. Permi
  • INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE
    Publication number: 20090143312
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: February 14, 2008
    Publication date: June 4, 2009
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE
    Publication number: 20090022688
    Abstract: The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt, or mixtures thereof, that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    Type: Application
    Filed: July 8, 2008
    Publication date: January 22, 2009
    Inventors: Luc J. Farmer, Robert B. Perni, Govinda Rao Bhisetti, Keith P. Wilson
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 7388017
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: June 27, 2003
    Date of Patent: June 17, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D Tung, Scott L Harbeson, David D Deininger, Mark A Murcko, Govinda R Bhisetti, Luc J Farmer
  • Thiazoles useful as inhibitors of protein kinases
    Patent number: 7276502
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: October 2, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy Brenchley, Luc J. Farmer, Edmund M. Harrington, Ronald Knegtel, Michael O'Donnell, Francesco G. Salituro, John R. Studley, Jian Wang
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7273885
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: September 25, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Patent number: 7241796
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: October 24, 2002
    Date of Patent: July 10, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie, Jr.
  • Bridged bicyclic serine protease inhibitors
    Patent number: 6909000
    Abstract: The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: June 21, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, Lawrence F. Courtney, John van Drie
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Publication number: 20040266731
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: June 27, 2003
    Publication date: December 30, 2004
    Inventors: Roger D. Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Thiazoles useful as inhibitors of protein kinases
    Publication number: 20040235834
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: March 25, 2004
    Publication date: November 25, 2004
    Inventors: Luc J. Farmer, Edmund Martin Harrington, Francesco G. Salituro, Jian Wang
  • Steroid receptor modulator compounds and methods
    Publication number: 20040186132
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Application
    Filed: December 17, 2003
    Publication date: September 23, 2004
    Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Publication number: 20040077600
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Application
    Filed: July 7, 2003
    Publication date: April 22, 2004
    Inventors: Roger D. Tung, Govinda Rao Bhisetti, Luc J. Farmer
  • Steroid receptor modulator compounds and methods
    Patent number: 6696459
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: February 24, 2004
    Assignee: Ligand Pharmaceuticals Inc.
    Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi, Lawrence G. Hamann, Luc J. Farmer, Robert L. Davis
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20040018986
    Abstract: The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.
    Type: Application
    Filed: April 11, 2003
    Publication date: January 29, 2004
    Inventors: Janos Pitlik, Kevin M. Cottrell, Luc J. Farmer, Robert B. Perni, Lawrence F. Courtney, John H. van Drie, Mark A. Murcko
  • Dimer-selective RXR modulators and methods for their use
    Publication number: 20040019072
    Abstract: Dimer-selective RXR modulator compounds having agonist, partial agonist and/or antagonist activity in the context of an RXR homodimer and/or RXR heterodimers are provided. Also provided are pharmaceutical compositions incorporating such dimer-selective RXR modulator compounds and methods for their therapeutic use.
    Type: Application
    Filed: February 5, 2003
    Publication date: January 29, 2004
    Inventors: Stacie Canan-Koch, Chan K. Hwang, Marcus F. Boehm, Beth Ann Badea, Laura J. Dardashti, Lin Zhang, Alex M. Nadzan, Richard A. Heyman, Ranjan Mukherjee, Deepak S. Lala, Luc J. Farmer
  • Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
    Patent number: 6617309
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: September 9, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D Tung, Scott L. Harbeson, David D. Deininger, Mark A. Murcko, Govinda R. Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly HCV NS3 protease
    Patent number: 6608067
    Abstract: The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: August 19, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Roger D. Tung, Govinda Rao Bhisetti, Luc J. Farmer
  • Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
    Publication number: 20030134889
    Abstract: The present invention relates to peptidomimetic compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: October 24, 2002
    Publication date: July 17, 2003
    Inventors: Luc J. Farmer, Robert B. Perni, Janos Pitlik, John H. van Drie
  • Bridged bicyclic serine protease inhibitors
    Publication number: 20030119752
    Abstract: The present invention relates to peptidomimetic compounds which inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The compounds of this invention have a bridged bicyclic moiety at the P2 position. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention.
    Type: Application
    Filed: July 11, 2002
    Publication date: June 26, 2003
    Inventors: Luc J. Farmer, Janos Pitlik, Robert B. Perni, Lawrence F. Courtney, John van Drie